Neuroimaging Biomarkers

Alzheimer’s disease Biomarkers, with emphasis on cerebrospinal fluid biomarkers and neuroimaging. Mild Cognitive Impairment (MCI) of Neuroimaging-biomarkers allow an early diagnosis in preclinical stages of Alzheimer’s disease. Biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. The dynamic measures of these imaging biomarkers are used to predict the disease progression in the early stages and improve the assessment of therapeutic efficacy in these diseases in future clinical trials

  • Neurogenesis & Neuron Regeneration
  • Structural Neuroimaging
  • Neuropathology
  • Cerebrospinal fluid biomarker
  • Structural and functional biomarkers